AAP
ACTU

Arax Advisory Partners’s Actuate Therapeutics ACTU Stock Holding History

Arax Advisory Partners’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25 Buy
+9
New +$37 ﹤0.01% 3699
2025
Q4 		– Sell
-60
Closed -$401 – 4602
2025
Q3 		$401 Buy
+60
New +$435 ﹤0.01% 3389

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's ACTU Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in Actuate Therapeutics (ACTU) in Q1 2026: 9 shares worth $25. The stake represents ﹤0.01% of the portfolio and ranks #3699 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in ACTU as recently as Q3 2025.

Arax Advisory Partners first reported a position in ACTU in Q3 2025 and has held it in 2 quarters since. The position peaked at $401 in Q3 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Arax Advisory Partners held 9 shares of Actuate Therapeutics worth $25 as of Q1 2026.
  • Actuate Therapeutics was a new Arax Advisory Partners position in Q1 2026.
  • Actuate Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3699 holding.
  • Arax Advisory Partners first reported a position in Actuate Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's Actuate Therapeutics position peaked at $401 in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.